Gopa Iyer

Active 2011–2025

115
Papers
23,864
Citations
55
h-index
103
i10-index

Citations

Citations per year for Gopa Iyer1952: 1 citations1976: 2 citations1977: 1 citations1992: 2 citations1998: 1 citations1999: 1 citations2004: 2 citations2007: 1 citations2009: 5 citations2010: 3 citations2012: 4 citations2013: 24 citations2014: 79 citations2015: 73 citations2016: 103 citations2017: 165 citations2018: 319 citations2019: 1,009 citations2020: 1,494 citations2021: 1,472 citations2022: 1,230 citations2023: 986 citations2024: 1,622 citations2025: 836 citations2026: 32 citations1953–1975: no citations, so these years are not shown1978–1991: no citations, so these years are not shown1993–1997: no citations, so these years are not shown2000–2003: no citations, so these years are not shown2005–2006: no citations, so these years are not shown2008: no citations, so this year is not shown2011: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,894 citing papers, 28.3% of this breakdownChina: 1,764 citing papers, 12.8% of this breakdownUnited Kingdom: 813 citing papers, 5.9% of this breakdownItaly: 698 citing papers, 5.1% of this breakdownGermany: 689 citing papers, 5% of this breakdownFrance: 536 citing papers, 3.9% of this breakdownCanada: 487 citing papers, 3.5% of this breakdownSpain: 487 citing papers, 3.5% of this breakdownJapan: 455 citing papers, 3.3% of this breakdownNetherlands: 393 citing papers, 2.8% of this breakdownSwitzerland: 326 citing papers, 2.4% of this breakdownAustralia: 317 citing papers, 2.3% of this breakdown
0%28.3%Other 21.2%

Fields

  • Medicine62.2%
  • Biochemistry, Genetics and Molecular Biology32.3%
  • Immunology and Microbiology2.8%
  • Computer Science1.3%
  • Engineering0.3%
  • Neuroscience0.2%
  • Other0.9%

Topics

  • Cancer Genomics and Diagnostics8.7%
  • Cancer Immunotherapy and Biomarkers8.1%
  • Bladder and Urothelial Cancer Treatments4.6%
  • Lung Cancer Treatments and Mutations3.8%
  • Ferroptosis and cancer prognosis3.1%
  • Urinary and Genital Oncology Studies2.4%
  • Other69.3%

Coauthors

All papers

Open in search
  1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris - Nature Genetics 2019 cited by 4,358

  2. OncoKB: A Precision Oncology Knowledge Base

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio Omuro, Michael A. Postow, Dana E. Rathkopf, Alexander N. Shoushtari, Neerav Shukla, Martin H. Voss, Ederlinda Paraiso, Ahmet Zehir, Michael F. Berger, Barry S. Taylor, Leonard B. Saltz, Gregory J. Riely, Marc Ladanyi, David M. Hyman, José Baselga, Paul Sabbatini, David B. Solit, Nikolaus Schultz - JCO Precision Oncology 2017 cited by 2,698

  3. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laetitia Borsu, Justyna Sadowska, Jacklyn Casanova, Ruben Bacares, Iwona Kiecka, Anna Razumova, Julie B Son, Lisa Stewart, Tessara Baldi, Kerry Mullaney, Hikmat Al‐Ahmadie, Efsevia Vakiani, Adam Abeshouse, Alexander Penson, Philip Jonsson, Niedzica Camacho, Matthew T. Chang, Helen Won, Benjamin Groß, Ritika Kundra, Zachary Heins, Hsiao‐Wei Chen, Sarah Phillips, Hongxin Zhang, Jiaojiao Wang, Angelica Ochoa, Jonathan Wills, Michael Eubank, Stacy B. Thomas, Stuart M. Gardos, Dalicia N. Reales, Jesse Galle, Robert Durany, Roy Cambria, Wassim Abida, Andrea Cercek, Darren R. Feldman, Mrinal M. Gounder, A. Ari Hakimi, James J. Harding, Gopa Iyer, Yelena Y. Janjigian, Emmet Jordan, Ciara M. Kelly, Maeve A. Lowery, Luc G.T. Morris, Antonio Omuro, Nitya Raj, Pedram Razavi, Alexander N. Shoushtari, Neerav Shukla, Tara E. Soumerai, Anna M. Varghese, Rona Yaeger, Jonathan Coleman, Bernard H. Bochner, Gregory J. Riely, Leonard B. Saltz, Howard I. Scher, Paul Sabbatini, Mark E. Robson, David S. Klimstra, Barry S. Taylor, José Baselga, Nikolaus Schultz, David M. Hyman, Maria E. Arcila, David B. Solit, Marc Ladanyi, Michael F. Berger - Nature Medicine 2017 cited by 3,517

  4. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 914

  5. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yelena Y. Janjigian, Michael J. Morris, Robert J. Motzer, Eileen M. O’Reilly, Michael A. Postow, Nitya Raj, Gregory J. Riely, Mark E. Robson, Jonathan E. Rosenberg, Anton Safonov, Alexander N. Shoushtari, William D. Tap, Min Yuen Teo, Anna M. Varghese, Martin H. Voss, Rona Yaeger, Marjorie G. Zauderer, Nadeem R. Abu‐Rustum, Julio García‐Aguilar, Bernard H. Bochner, A. Ari Hakimi, William R. Jarnagin, David R. Jones, Daniela Molena, Luc G.T. Morris, Eric Rios‐Doria, Paul Russo, Samuel Singer, Vivian E. Strong, Debyani Chakravarty, Lora H. Ellenson, Anuradha Gopalan, Jorge S. Reis‐Filho, Britta Weigelt, Marc Ladanyi, Mithat Gönen, Sohrab P. Shah, Joan Massagué, Jianjiong Gao, Ahmet Zehir, Michael F. Berger, David B. Solit, Samuel F. Bakhoum, Francisco Sánchez-Vega, Nikolaus Schultz - Cell 2022 cited by 663

  6. Genome doubling shapes the evolution and prognosis of advanced cancers

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Genetics 2018 cited by 692

  7. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Drilon, James J. Harding, Gopa Iyer, Barry S. Taylor, Michael F. Berger, Richard E. Cutler, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Cynthia Farrell, Alshad S. Lalani, Richard Bryce, Carlos L. Arteaga, Funda Meric‐Bernstam, José Baselga, David B. Solit - Nature 2018 cited by 788

  8. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alison Y. Zhang, Hans Prenen, Jean‐Charles Goeminne, Jean‐Pascal Machiels, Sylvie Rottey, Marcelo Corassa, Graziela Zibetti Dal Molin, Katsuki Arima Tiscoski, Denis L. Jardim, Milena Perez Mak, Wei Fu, Herui Yao, Jing Huang, Haiping Jiang, Jing Huang, Baoshi Chen, Dong Yan, Yu Yang, Yohann Loriot, Christophe Le Tourneau, Nicolas Penel, Sébastien Salas, Jean‐Yves Blay, Pierre-Emmanuel Brachet, Xavier Durando, Sheik Emambux, Alain Ravaud, Gunnar Folprecht, Dirk Arnold, Martin Schüler, Marit Ahrens, Alexander Golf, Georg Martin Haag, Florian Lordick, Alexander Desuki, Marina Elena Cazzaniga, Fortunato Ciardiello, Michèle Milella, Takafumi Koyama, Yoshiki Hirooka, Wataru Okamoto, Kenjiro Aogi, Yasutoshi Kuboki, Jung-Yun Lee, Sung‐Bae Kim, Myung‐Ju Ahn, Jong Hee Chang, Yongman Kim, Do‐Hyun Nam, Jaesung Park, Iwona Ługowska, Luis Paz‐Ares, Víctor Moreno, Andrés Cervantes, Mariona Calvo, Alejandro Falcón, Antonio González, Josep Tabernero, A. Martinez Bueno, Javier García-Corbacho, Federico Longo, Chia‐Jui Yen, Jen‐Shi Chen, Ming‐Feng Hou, Yee Chao, Kun‐Ming Rau, Tai‐Jan Chiu, Yin‐Hsun Feng, Chih‐Hung Hsu, Wen‐Tsung Huang and 33 more - The Lancet Oncology 2023 cited by 200

  9. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)

    Authors: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 135

  10. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2014 cited by 590

  11. Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stacey Gabriel, Alan D. D’Andrea, Levi A. Garraway, Jonathan E. Rosenberg - Cancer Discovery 2014 cited by 624

  12. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 552

  13. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael J. Morris, Robert J. Motzer, Eileen M. O’Reilly, Michael A. Postow, Nitya Raj, Gregory J. Riely, Mark E. Robson, Jonathan E. Rosenberg, Anton Safonov, Alexander N. Shoushtari, William D. Tap, Min Yuen Teo, Anna M. Varghese, Martin H. Voss, Rona Yaeger, Marjorie G. Zauderer, Nadeem R. Abu‐Rustum, Julio García‐Aguilar, Bernard H. Bochner, A. Ari Hakimi, William R. Jarnagin, David R. Jones, Daniela Molena, Luc G.T. Morris, Eric Rios‐Doria, Paul Russo, Samuel Singer, Vivian E. Strong, Debyani Chakravarty, Lora H. Ellenson, Anuradha Gopalan, Jorge S. Reis‐Filho, Britta Weigelt, Marc Ladanyi, Mithat Gönen, Sohrab P. Shah, Joan Massagué, Jianjiong Gao, Ahmet Zehir, Michael F. Berger, David B. Solit, Samuel F. Bakhoum, Francisco Sánchez-Vega, Nikolaus Schultz - 2021 cited by 69

  14. OncoTree: A Cancer Classification System for Precision Oncology

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah P. Suehnholz, Moriah H. Nissan, Gopa Iyer, Rajmohan Murali, Nancy Bouvier, Robert A. Soslow, David M. Hyman, Anas Younes, Andrew M. Intlekofer, James J. Harding, Richard D. Carvajal, Paul Sabbatini, Ghassan K. Abou‐Alfa, Luc G.T. Morris, Yelena Y. Janjigian, Meighan M. Gallagher, Tara A. Soumerai, Ingo K. Mellinghoff, A. Ari Hakimi, Matthew G. Fury, Jason T. Huse, Aditya Bagrodia, Meera Hameed, Stacy B. Thomas, Stuart M. Gardos, Ethan Cerami, Tali Mazor, Priti Kumari, Pichai Raman, Priyanka Shivdasani, Suzanne P. MacFarland, Scott Newman, Angela J. Waanders, Jianjiong Gao, David B. Solit, Nikolaus Schultz - JCO Clinical Cancer Informatics 2021 cited by 150

  15. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alan Li, Emily S. Lebow, Anita S. Bowman, Donna C. Ferguson, Ying Liu, Douglas A. Mata, Rohit Sharma, Soo‐Ryum Yang, Tejus Bale, Jamal Benhamida, Jason C. Chang, Snjezana Doğan, Meera Hameed, Jaclyn F. Hechtman, Christine Moung, Dara S. Ross, Efsevia Vakiani, Chad Vanderbilt, JinJuan Yao, Pedram Razavi, Lillian M. Smyth, Sarat Chandarlapaty, Gopa Iyer, Wassim Abida, James J. Harding, Benjamin A. Krantz, Eileen M. O’Reilly, Helena A. Yu, Bob T. Li, Charles M. Rudin, Luis A. Díaz, David B. Solit, Maria E. Arcila, Marc Ladanyi, Brian Houck‐Loomis, Dana W.Y. Tsui, Michael F. Berger, Ahmet Zehir, Ryma Benayed - Nature Communications 2021 cited by 183

  16. LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Science Translational Medicine 2021 cited by 98

  17. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2017 cited by 372

  18. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 82

  19. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis

    Authors: , , , , , , , , , , , , , , , , , , , , - PLoS Medicine 2017 cited by 367

  20. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jonathan E. Rosenberg, Min Yuen Teo, Dean F. Bajorin - Journal of Clinical Oncology 2023 cited by 105

  21. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 cited by 162

  22. Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Timothy F. Donahue, Alvin C. Goh, William C. Huang, Dean F. Bajorin, Gopa Iyer, Bernard H. Bochner, Arjun Vasant Balar, Amir Mortazavi, Jonathan E. Rosenberg - Journal of Clinical Oncology 2022 cited by 99

  23. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2022 cited by 70

  24. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 cited by 283